Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27

Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary Sjögren’s disease

Pro-forma cash and investment balance of $514.5 million expected to provide runway into early 2029

BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

“We continued to make meaningful progress in 2026 with telitacicept receiving its fourth and fifth commercial approvals in China for the treatment of Sjögren’s disease and IgA nephropathy and its Phase 3 TELIGAN trial in IgA nephropathy being featured in The New England Journal of Medicine. Enrollment in our global studies, UPSTREAM MG and UPSTREAM SjD, remains on track, bringing us closer to demonstrating telitacicept’s potential as a first-in-class and best-in-disease BAFF/APRIL therapy in both indications. We are encouraged by our growing momentum, the caliber of talent joining Vor, and the opportunity ahead,” said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio.
Program Highlights

Telitacicept: a potential best- and first-in-class dual BAFF/APRIL inhibitor in development for generalized myasthenia gravis (gMG) and primary Sjögren’s disease (SjD)

Generalized Myasthenia Gravis

• UPSTREAM MG
  • Enrollment ongoing in global randomized, double-blind, placebo-controlled Phase 3 registrational trial with an open-label extension assessing the efficacy and safety of telitacicept in gMG
  • Topline data anticipated in 1H 2027
    

Primary Sjögren’s Disease

• UPSTREAM SjD
  • Enrollment ongoing in global randomized, double-blind, placebo-controlled Phase 3 registrational trial assessing the efficacy and safety of telitacicept in SjD

Corporate Updates

• Appointed David Zaccardelli, Pharm.D., former Chief Executive Officer and President of Verona Pharma, to its Board of Directors
• Announced China’s National Medicinal Products Administration (NMPA) approved telitacicept for the treatment of adult patients with SjD and IgA nephropathy (IgAN)
• Results from the Phase 3 TELIGAN trial evaluating telitacicept in IgAN in China were published in The New England Journal of Medicine
  

Second Quarter 2026 Financial Results

• Cash Position: Cash, cash equivalents and marketable securities were $466.1 million as of June 30, 2026, which together with the $48.4 million net proceeds from at-the-market sales during July 2026, are projected to fund operations into early 2029.
  

• Research & Development (R&D) Expenses: R&D expenses for the second quarter of 2026 were $25.9 million, compared to $261.5 million for the second quarter of 2025. The decrease of $235.6 million was primarily due to the $222.6 million expense incurred for the Telitacicept License Agreement in the second quarter of 2025, as well as costs incurred in connection with the termination of employees and the prior lease in the same quarter in 2025. These decreases were partially offset by the increase in spend for our new programs, telitacicept in gMG and SjD in the second quarter of 2026.
  

• General & Administrative (G&A) Expenses: G&A expenses for the second quarter of 2026 were $21.9 million, compared to $12.8 million for the second quarter of 2025. The increase of $9.1 million was primarily due to increases in stock-based compensation compared to the prior year period. The increase was also attributable to an increase in personnel-related expenses and commercial-related expenses.
  

• Net Loss: Net loss for the second quarter of 2026 was $62.8 million, compared to $1,573.7 million net loss for the second quarter of 2025. The decrease in loss of $1,510.9 million was primarily due to the change in fair value of the outstanding liability-classified warrants in the second quarter of 2026 compared to the change in fair value recognized in the second quarter of 2025.
  

About Telitacicept
Telitacicept is a novel recombinant fusion protein designed to treat autoimmune diseases through dual inhibition of BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology.

Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), generalized myasthenia gravis (gMG), IgA nephropathy (IgAN), and Sjögren’s disease (SjD).

Vor Bio is advancing global development programs across major autoimmune indications, including a global Phase 3 trial in gMG and SjD, to support potential regulatory approvals in the United States, Europe, and Japan.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Vor Bio routinely posts information that may be important to investors in the “Investors” section of its website. The Company encourages investors to consult that section of its website regularly.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “continue,” “could,” “design,” “expect,” “initiate,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding telitacicept’s potential as a first-in-class and best-in-disease BAFF/APRIL therapy for gMG and SjD; Vor Bio’s projected cash runway; Vor Bio’s development and commercialization plans for telitacicept, including having topline data from the UPSTREAM-MG trial in the first half of 2027; and other statements that are not historical fact.

Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including the data for our product candidates may not be sufficient for obtaining regulatory approval to commercialize products; we may not be able to execute our business plans, including meeting our planned clinical and regulatory milestones and timelines, and possible limitations of financial and other resources. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Statements regarding Vor Bio’s cash runway do not indicate when or if Vor Bio may access the capital markets.

Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com